EUVIMEDEUVIMED entdecken
Crossref

Indomethacin Does Not Reduce Post-ERCP Pancreatitis in High-Risk Patients Receiving Pancreatic Stenting

Bingqing Bai, Shaofei Wang, Yemei Du, Mengwen Li, Qiming Huang, Sisi Liu, Chenyu Zhang, Yuanyuan Fang, Xinwen Chen, Jianglong Hong, Yang Li, Zhangwei Xu und 4 weitere

Digestive Diseases and Sciences · 2024

DOI: 10.1007/s10620-024-08542-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Bingqing Bai und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, China. Hauptthemen laut MEDLINE: Indomethacin, Cholangiopancreatography, Endoscopic Retrograde, Pancreatitis, Stents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Rectal indomethacin reduces pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). However, there is insufficient evidence regarding its added benefits in patients already receiving prophylactic pancreatic stenting. Our goal was to evaluate the impact of indomethacin in high-risk patients undergoing pancreatic stenting. METHODS: A cohort study was conducted on all patients who underwent the rescue cannulation technique for challenging bile duct cannulation (selected high-risk patients). Patients were split into two groups based on the prophylaxis method for post-ERCP pancreatitis (PEP): one receiving a combination of indomethacin and pancreatic stenting, while the other received pancreatic stenting alone. Comparative analyses were carried out on PEP, hyperamylasemia, gastrointestinal bleeding, and postoperative hospital stay among post-ERCP pancreatitis patients. RESULTS: Between November 2017 and May 2023, a total of 607 patients with native papillae were enrolled, with 140 grouped into the indomethacin plus stent group and 467 into the stent alone group. The overall PEP rate was 4.4% in the entire cohort, with no statistical differences observed between the groups in terms of PEP rates (P = 0.407), mild PEP (P = 0.340), moderate to severe PEP (P = 1.000), hyperamylasemia (P = 0.543), gastrointestinal bleeding (P = 0.392), and postoperative hospital stay (P = 0.521). Furthermore, sensitivity analysis using multivariable analysis also validated these findings. CONCLUSIONS: Indomethacin did not reduce the incidence or severity of PEP in high-risk patients who routinely received prophylactic pancreatic stent placement. Therefore, the additional administration of rectal indomethacin to further mitigate PEP appears to be not necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndomethacinCholangiopancreatography, Endoscopic RetrogradePancreatitisStentsHumansFemaleMaleMiddle AgedAgedAnti-Inflammatory Agents, Non-SteroidalAdministration, RectalRetrospective StudiesLength of StayRisk FactorsCohort StudiesPostoperative Complications

Stichwörter der Autor:innen

Adverse effectsCholangiopancreatographyEndoscopic retrogradeHumansIndomethacinPancreatitis

Substanzen

IndomethacinAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, China.
  • Department of Gastroenterology, Suzhou First People's Hospital, Suzhou, 234000, Anhui, China.
  • Department of Gastroenterology, Xuancheng People's Hospital, Xuancheng, 242000, Anhui, China.
  • Department of Gastroenterology, Fuyang People's Hospital, Fuyang, 236012, Anhui, China.
  • Department of Endoscopy, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, China.
  • Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, China. meiqiaomq@aliyun.com.

Zitieren

APA

Bai, B., Wang, S., Du, Y., Li, M., Huang, Q., Liu, S., Zhang, C., Fang, Y., Chen, X., Hong, J., Li, Y., Xu, Z., Liu, X., Hong, R., Bao, J., & Mei, Q. (2024). Indomethacin Does Not Reduce Post-ERCP Pancreatitis in High-Risk Patients Receiving Pancreatic Stenting. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08542-2

Vancouver

Bai B, Wang S, Du Y, Li M, Huang Q, Liu S, et al. Indomethacin Does Not Reduce Post-ERCP Pancreatitis in High-Risk Patients Receiving Pancreatic Stenting. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08542-2

BibTeX
@article{Bai2024,
  author = {Bai, Bingqing and Wang, Shaofei and Du, Yemei and Li, Mengwen and Huang, Qiming and Liu, Sisi and Zhang, Chenyu and Fang, Yuanyuan and Chen, Xinwen and Hong, Jianglong and Li, Yang and Xu, Zhangwei and Liu, Xiaochang and Hong, Rutao and Bao, Junjun and Mei, Qiao},
  title = {Indomethacin Does Not Reduce Post-ERCP Pancreatitis in High-Risk Patients Receiving Pancreatic Stenting},
  journal = {Digestive Diseases and Sciences},
  year = {2024},
  doi = {10.1007/s10620-024-08542-2}
}
Kostenlos starten →